Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Ischemic Heart Disease

Free Subscription Articles published in JAMA Retrieve available abstracts of 119 articles: HTML format

Single Articles

June 2026
1. BADVE SV, Perkovic V, Jha V, Ramachandran R, et al
   Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial.
   JAMA. 2026 Jun 4. doi: 10.1001/jama.2026.9379.
   PubMed     Abstract available
   
   
   
2. 
   Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: Research Summary.
   JAMA. 2026 Jun 4:e269463. doi: 10.1001/jama.2026.9463.
   PubMed    
   
   
   
3. BANSAL N, Winkelmayer WC
   Rivaroxaban for Cardiovascular Disease Prevention in Chronic Kidney Disease: High Risk, but No Reward?
   JAMA. 2026 Jun 4. doi: 10.1001/jama.2026.9780.
   PubMed    
   
   
   May 2026
4. MORELLI N, Marotti C, Gallerini S
   Tenecteplase for Acute Non-Large Vessel Occlusion After Ischemic Stroke.
   JAMA. 2026 May 27. doi: 10.1001/jama.2026.4816.
   PubMed    
   
   
   
5. MA G, Zhong L, Hao J
   Tenecteplase for Acute Non-Large Vessel Occlusion After Ischemic Stroke-Reply.
   JAMA. 2026 May 27. doi: 10.1001/jama.2026.4819.
   PubMed    
   
   
   
6. ANDERER S
   Cognitive Decline May Precede Cardiovascular Events by Up to 8 Years.
   JAMA. 2026 May 15. doi: 10.1001/jama.2026.6183.
   PubMed    
   
   
   
7. XIONG Y, Che F, Wang H, Hao M, et al
   Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial.
   JAMA. 2026 May 8. doi: 10.1001/jama.2026.4292.
   PubMed     Abstract available
   
   
   
8. 
   Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: Research Summary.
   JAMA. 2026 May 8:e264503. doi: 10.1001/jama.2026.4503.
   PubMed    
   
   
   
9. ANDERER S
   Syphilis Linked to Higher Risk of Some Cardiovascular Outcomes.
   JAMA. 2026 May 8. doi: 10.1001/jama.2026.2132.
   PubMed    
   
   
   
10. 
    Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: Research Summary.
    JAMA. 2026 May 8:e265288. doi: 10.1001/jama.2026.5288.
    PubMed    
    
    
    
11. LIU X, Zhang F, Zhang C, Li Z, et al
    Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial.
    JAMA. 2026 May 8:e265245. doi: 10.1001/jama.2026.5245.
    PubMed     Abstract available
    
    
    April 2026
12. BOND RM, Debbink MP, Geller A, Lieu TA, et al
    Preventing Pregnancy-Related Cardiovascular Disease Burden: A Report From the National Academies of Sciences, Engineering, and Medicine.
    JAMA. 2026 Apr 21. doi: 10.1001/jama.2026.6717.
    PubMed    
    
    
    March 2026
13. WINCHESTER DE, Mehta JJ, Alexander JT
    Perioperative Cardiovascular Medication Management for Noncardiac Surgery.
    JAMA. 2026 Mar 31. doi: 10.1001/jama.2026.0067.
    PubMed    
    
    
    
14. LANPHEAR BP
    Reframing the Coronary Heart Disease Epidemic-The Role of Lead Exposure.
    JAMA. 2026 Mar 30. doi: 10.1001/jama.2026.3041.
    PubMed    
    
    
    
15. STANAWAY JD, Spearman S, DeCleene NK, Garcia V, et al
    Lead-Attributable Cardiovascular Disease Burden: Global Burden of Disease Study 2023.
    JAMA. 2026 Mar 30:e262197. doi: 10.1001/jama.2026.2197.
    PubMed     Abstract available
    
    
    
16. VOHRA AS, Alexander JT, Shah AP
    Management of Acute Coronary Syndrome.
    JAMA. 2026 Mar 30. doi: 10.1001/jama.2026.1214.
    PubMed    
    
    
    
17. 
    Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Research Summary.
    JAMA. 2026 Mar 28:e263429. doi: 10.1001/jama.2026.3429.
    PubMed    
    
    
    
18. MARSTON NA, Bohula EA, Bhatia AK, De Ferrari GM, et al
    Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
    JAMA. 2026 Mar 28:e263277. doi: 10.1001/jama.2026.3277.
    PubMed     Abstract available
    
    
    
19. ABBASI J
    MASALA Study Suggests Earlier Cardiovascular Vigilance Needed for People With South Asian Ancestry.
    JAMA. 2026 Mar 13. doi: 10.1001/jama.2026.1798.
    PubMed    
    
    
    February 2026
20. EINSTEIN AJ, Williams MC, Weir-McCall JR, Shaw LJ, et al
    Worldwide Radiation Dose in Coronary Artery Disease Diagnostic Imaging.
    JAMA. 2026 Feb 25:e260703. doi: 10.1001/jama.2026.0703.
    PubMed     Abstract available
    
    
    
21. ANDERER S
    Cardiovascular Disease Risk Climbs Earlier for Men.
    JAMA. 2026 Feb 20. doi: 10.1001/jama.2025.26395.
    PubMed    
    
    
    
22. XU C, Qu JZ, Wang D
    Determining Duration of Oral Anticoagulation Treatment for New-Onset AF After Coronary Artery Bypass Grafting.
    JAMA. 2026 Feb 9. doi: 10.1001/jama.2025.25368.
    PubMed    
    
    
    
23. HERRMANN FEM, Jeppsson A, Hagl C
    Determining Duration of Oral Anticoagulation Treatment for New-Onset AF After Coronary Artery Bypass Grafting -Reply.
    JAMA. 2026 Feb 9. doi: 10.1001/jama.2025.25371.
    PubMed    
    
    
    
24. MA G, Mo R, Zuo Y, Ma Q, et al
    Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke: The OPTION Randomized Clinical Trial.
    JAMA. 2026 Feb 5. doi: 10.1001/jama.2026.0210.
    PubMed     Abstract available
    
    
    
25. 
    Tenecteplase for Acute Non-Large Vessel Occlusion Ischemic Stroke: Research Summary.
    JAMA. 2026 Feb 5:e260263. doi: 10.1001/jama.2026.0263.
    PubMed    
    
    
    January 2026
26. RUBIN R
    Stress May Link Depression and Anxiety to Cardiovascular Disease.
    JAMA. 2026 Jan 23. doi: 10.1001/jama.2025.25865.
    PubMed    
    
    
    
27. BERGSTROM G, Engstrom G, Bjornson E, Adiels M, et al
    Coronary Computed Tomography Angiography in Prediction of First Coronary Events.
    JAMA. 2026;335:245-254.
    PubMed     Abstract available
    
    
    
28. COMBES A, Saura O, Nesseler N, Lebbah S, et al
    Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial.
    JAMA. 2026;335:60-69.
    PubMed     Abstract available
    
    
    
29. PANT S
    RSV Infection Associated With Increased Cardiovascular Risks.
    JAMA. 2026 Jan 2. doi: 10.1001/jama.2025.23005.
    PubMed    
    
    
    November 2025
30. HSU M, Shah A, Jordan A, Gold MS, et al
    Therapeutic Use of Cannabis and Cannabinoids: A Review.
    JAMA. 2025 Nov 26. doi: 10.1001/jama.2025.19433.
    PubMed     Abstract available
    
    
    
31. PANT S
    Meta-Analysis: Viral Infections May Raise Cardiovascular Risks.
    JAMA. 2025 Nov 14. doi: 10.1001/jama.2025.19736.
    PubMed    
    
    
    
32. KOUGIAS P, Sharath SE, Zhan M, Carson JL, et al
    Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial.
    JAMA. 2025 Nov 8:e2520841. doi: 10.1001/jama.2025.20841.
    PubMed     Abstract available
    
    
    
33. PANT S
    FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes.
    JAMA. 2025 Nov 7. doi: 10.1001/jama.2025.19724.
    PubMed    
    
    
    
34. PANT S
    Nighttime Light Exposure Associated With Increased Cardiovascular Risk.
    JAMA. 2025 Nov 7. doi: 10.1001/jama.2025.19729.
    PubMed    
    
    
    October 2025
35. ABBASI J
    New Guidance on Cardiovascular Disease and COVID-19-From Infection to Long COVID to Vaccination.
    JAMA. 2025 Oct 24. doi: 10.1001/jama.2025.18834.
    PubMed    
    
    
    
36. PAN Y, Miao Z, Huo X
    Intra-Arterial Tenecteplase After Successful Endovascular Therapy for Acute Stroke-Reply.
    JAMA. 2025 Oct 23. doi: 10.1001/jama.2025.16273.
    PubMed    
    
    
    
37. ZHAO YT
    Intra-Arterial Tenecteplase After Successful Endovascular Therapy for Acute Stroke.
    JAMA. 2025 Oct 23. doi: 10.1001/jama.2025.16270.
    PubMed    
    
    
    
38. PANT S
    Cardiovascular Conditions Lead Global Disease Burden Over the Past 30 Years.
    JAMA. 2025 Oct 17. doi: 10.1001/jama.2025.17515.
    PubMed    
    
    
    
39. HERRMANN FEM, Jeppsson A, Kirov H, Charitos EI, et al
    Long-Term Continuous Monitoring of New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting.
    JAMA. 2025 Oct 9:e2514891. doi: 10.1001/jama.2025.14891.
    PubMed     Abstract available
    
    
    September 2025
40. ZHU J, Zhang W
    Timing of Antihypertensive Medications and Cardiovascular Outcomes.
    JAMA. 2025 Sep 17. doi: 10.1001/jama.2025.12790.
    PubMed    
    
    
    
41. GAO M, Cao T, Wu Q
    Timing of Antihypertensive Medications and Cardiovascular Outcomes.
    JAMA. 2025 Sep 17. doi: 10.1001/jama.2025.12787.
    PubMed    
    
    
    
42. GARRISON SR, Kolber MR, Korownyk CS
    Timing of Antihypertensive Medications and Cardiovascular Outcomes-Reply.
    JAMA. 2025 Sep 17. doi: 10.1001/jama.2025.12796.
    PubMed    
    
    
    
43. CEDERNAES J, Benedict C
    Timing of Antihypertensive Medications and Cardiovascular Outcomes.
    JAMA. 2025 Sep 17. doi: 10.1001/jama.2025.12784.
    PubMed    
    
    
    
44. FENG S, Li H, Sun R
    Timing of Antihypertensive Medications and Cardiovascular Outcomes.
    JAMA. 2025 Sep 17. doi: 10.1001/jama.2025.12793.
    PubMed    
    
    
    
45. FREEDMAN AA, Perak AM, Ernst LM, Borders A, et al
    High Blood Pressure in Childhood and Premature Cardiovascular Disease Mortality.
    JAMA. 2025 Sep 7:e2514405. doi: 10.1001/jama.2025.14405.
    PubMed    
    
    
    
46. HOFMANN R, James S, Sundqvist MO, Warme J, et al
    Helicobacter pylori Screening After Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI SWEDEHEART Trial.
    JAMA. 2025 Sep 1:e2515047. doi: 10.1001/jama.2025.15047.
    PubMed     Abstract available
    
    
    August 2025
47. PUSTJENS TFS, Veenstra L, Camaro C, Ruiters AW, et al
    Fractional Flow Reserve-Guided Complete vs Culprit-Only Revascularization in Non-ST-Elevation Myocardial Infarction and Multivessel Disease: The SLIM Randomized Clinical Trial.
    JAMA. 2025 Aug 31:e2516189. doi: 10.1001/jama.2025.16189.
    PubMed     Abstract available
    
    
    
48. LASSEN MCH, Johansen ND, Christensen SH, Aliabadi N, et al
    Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial.
    JAMA. 2025 Aug 30:e2515405. doi: 10.1001/jama.2025.15405.
    PubMed     Abstract available
    
    
    
49. CHU HY, Murray AF
    Shot Through the Heart-Can RSV Vaccination Reduce Risk of Cardiovascular Outcomes?
    JAMA. 2025 Aug 30. doi: 10.1001/jama.2025.16705.
    PubMed    
    
    
    July 2025
50. WU J, Kanter GP, Wagner TH, Chu D, et al
    Impact of the MISSION Act on Quality and Outcomes of Major Cardiovascular Procedures Among Veterans.
    JAMA. 2025 Jul 31. doi: 10.1001/jama.2025.11661.
    PubMed     Abstract available
    
    
    
51. ANDERER S
    Invasive Approach Fails to Reduce Deaths in Older Adults With Acute Coronary Syndromes.
    JAMA. 2025 Jul 18. doi: 10.1001/jama.2025.10335.
    PubMed    
    
    
    
52. ANDERER S
    Obesity Drugs Considered First-Line Option for Cardiovascular Risk.
    JAMA. 2025 Jul 11. doi: 10.1001/jama.2025.10324.
    PubMed    
    
    
    
53. MIAO Z, Luo G, Song L, Sun D, et al
    Intra-arterial Tenecteplase for Acute Stroke After Successful Endovascular Therapy: The ANGEL-TNK Randomized Clinical Trial.
    JAMA. 2025 Jul 5:e2510800. doi: 10.1001/jama.2025.10800.
    PubMed     Abstract available
    
    
    
54. YADAV A, Usman MS, Gupta R
    Combining Coronary Calcium Score With Treatment in Familial Coronary Artery Disease.
    JAMA. 2025 Jul 2. doi: 10.1001/jama.2025.6482.
    PubMed    
    
    
    
55. MARWICK TH, Whitmore K, Nicholls SJ
    Combining Coronary Calcium Score With Treatment in Familial Coronary Artery Disease-Reply.
    JAMA. 2025 Jul 2. doi: 10.1001/jama.2025.6485.
    PubMed    
    
    
    June 2025
56. SAXENA M, Laffin L, Borghi C, Fernandez Fernandez B, et al
    Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.
    JAMA. 2025 Jun 30:e259413. doi: 10.1001/jama.2025.9413.
    PubMed     Abstract available
    
    
    May 2025
57. KIM JH, Rim AJ, Miller JT, Jackson M, et al
    Cardiac Arrest During Long-Distance Running Races.
    JAMA. 2025;333:1699-1707.
    PubMed     Abstract available
    
    
    
58. LEE CJ, Ihm SH, Shin DH, Jeong JO, et al
    Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial.
    JAMA. 2025 May 14:e255129. doi: 10.1001/jama.2025.5129.
    PubMed     Abstract available
    
    
    
59. GARRISON SR, Bakal JA, Kolber MR, Korownyk CS, et al
    Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial.
    JAMA. 2025 May 12:e254390. doi: 10.1001/jama.2025.4390.
    PubMed     Abstract available
    
    
    April 2025
60. PEI YY
    Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications.
    JAMA. 2025 Apr 9. doi: 10.1001/jama.2025.0688.
    PubMed    
    
    
    
61. HO PM, Glorioso TJ, Bull S
    Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications-Reply.
    JAMA. 2025 Apr 9. doi: 10.1001/jama.2025.0694.
    PubMed    
    
    
    
62. YUAN J, Zhao J, Lu K
    Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications.
    JAMA. 2025 Apr 9. doi: 10.1001/jama.2025.0691.
    PubMed    
    
    
    
63. ABRAMOWITZ SA, Levin MG, Damrauer SM
    Performance and Agreement of Coronary Heart Disease Polygenic Risk Scores-Reply.
    JAMA. 2025 Apr 7. doi: 10.1001/jama.2025.0621.
    PubMed    
    
    
    
64. SHAN D
    Performance and Agreement of Coronary Heart Disease Polygenic Risk Scores.
    JAMA. 2025 Apr 7. doi: 10.1001/jama.2025.0618.
    PubMed    
    
    
    
65. ANDERER S
    FDA Updates Testosterone Labeling for Blood Pressure and Cardiovascular Risks.
    JAMA. 2025 Apr 4. doi: 10.1001/jama.2025.3240.
    PubMed    
    
    
    March 2025
66. KRISHNAN V, Huang X, Perak AM, Coresh J, et al
    Discordance of 10- and 30-Year Predicted Risk for Cardiovascular Disease in US Adults.
    JAMA. 2025 Mar 31:e252868. doi: 10.1001/jama.2025.2868.
    PubMed    
    
    
    
67. RODGERS L
    7 Takeaways for Primary Care Clinicians From the Updated Acute Coronary Syndromes Guideline.
    JAMA. 2025 Mar 28. doi: 10.1001/jama.2025.2931.
    PubMed    
    
    
    
68. WU Y, Meng J, Gao S
    Zerlasiran for the Treatment of Atherosclerotic Cardiovascular Disease.
    JAMA. 2025 Mar 27. doi: 10.1001/jama.2025.0031.
    PubMed    
    
    
    
69. NISSEN SE
    Zerlasiran for the Treatment of Atherosclerotic Cardiovascular Disease-Reply.
    JAMA. 2025 Mar 27. doi: 10.1001/jama.2025.0034.
    PubMed    
    
    
    
70. NASIR K, Blankstein R
    Transforming the Cardiovascular Disease Prevention Paradigm: See Disease, Treat Disease.
    JAMA. 2025 Mar 5. doi: 10.1001/jama.2025.2323.
    PubMed    
    
    
    
71. NERLEKAR N, Vasanthakumar SA, Whitmore K, Soh CH, et al
    Effects of Combining Coronary Calcium Score With Treatment on Plaque Progression in Familial Coronary Artery Disease: A Randomized Clinical Trial.
    JAMA. 2025 Mar 5:e250584. doi: 10.1001/jama.2025.0584.
    PubMed     Abstract available
    
    
    February 2025
72. ANDERER S
    Supine Hypertension Linked to Cardiovascular Risk Regardless of Seated Blood Pressure.
    JAMA. 2025 Feb 21. doi: 10.1001/jama.2025.0544.
    PubMed    
    
    
    
73. DEMASI M, Redberg RF, Abramson JD
    Statins for Primary Prevention of Cardiovascular Disease.
    JAMA. 2025 Feb 12. doi: 10.1001/jama.2024.26588.
    PubMed    
    
    
    
74. LLOYD-JONES DM, Khan S
    Statins for Primary Prevention of Cardiovascular Disease-Reply.
    JAMA. 2025 Feb 12. doi: 10.1001/jama.2024.26594.
    PubMed    
    
    
    
75. DIAO JA, Wadhera RK, Manrai AK
    Statins for Primary Prevention of Cardiovascular Disease-Reply.
    JAMA. 2025 Feb 12. doi: 10.1001/jama.2024.26591.
    PubMed    
    
    
    January 2025
76. WILSON LM, Anderson TS
    Trends in Preventive Aspirin Use by Atherosclerotic Cardiovascular Risk.
    JAMA. 2025 Jan 22. doi: 10.1001/jama.2024.27333.
    PubMed    
    
    
    
77. HUANG J, Yang J, Liu C, Li L, et al
    Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke: The POST-TNK Randomized Clinical Trial.
    JAMA. 2025 Jan 13. doi: 10.1001/jama.2024.23466.
    PubMed     Abstract available
    
    
    December 2024
78. ANDERER S
    Cardiovascular Disease Deaths Climb in Rural US, Particularly Among Younger Adults.
    JAMA. 2024 Dec 20. doi: 10.1001/jama.2024.25507.
    PubMed    
    
    
    
79. HO PM, Glorioso TJ, Allen LA, Blankenhorn R, et al
    Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications: A Randomized Pragmatic Trial.
    JAMA. 2024 Dec 2:e2421739. doi: 10.1001/jama.2024.21739.
    PubMed     Abstract available
    
    
    November 2024
80. ABRAMOWITZ SA, Boulier K, Keat K, Cardone KM, et al
    Evaluating Performance and Agreement of Coronary Heart Disease Polygenic Risk Scores.
    JAMA. 2024 Nov 16:e2423784. doi: 10.1001/jama.2024.23784.
    PubMed     Abstract available
    
    
    
81. KHAN SS, Pencina MJ
    Polygenic Risk Scores for Coronary Heart Disease: An Unfulfilled Promise of Precision Medicine.
    JAMA. 2024 Nov 16. doi: 10.1001/jama.2024.24037.
    PubMed    
    
    
    October 2024
82. ANDERER S
    Recalled Cardiovascular Devices Rarely Undergo Sufficient Testing.
    JAMA. 2024 Oct 11. doi: 10.1001/jama.2024.20123.
    PubMed    
    
    
    September 2024
83. TU WJ, Zhao J
    Prognostic Value of Cardiovascular Biomarkers.
    JAMA. 2024 Sep 18. doi: 10.1001/jama.2024.16519.
    PubMed    
    
    
    
84. MANGALESH S, Nanna MG
    Prognostic Value of Cardiovascular Biomarkers.
    JAMA. 2024 Sep 18. doi: 10.1001/jama.2024.16522.
    PubMed    
    
    
    
85. NEUMANN JT, Twerenbold R, Ojeda F
    Prognostic Value of Cardiovascular Biomarkers-Reply.
    JAMA. 2024 Sep 18. doi: 10.1001/jama.2024.16525.
    PubMed    
    
    
    
86. MENG X, Li S, Dai H, Lu G, et al
    Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial.
    JAMA. 2024 Sep 12. doi: 10.1001/jama.2024.14721.
    PubMed     Abstract available
    
    
    August 2024
87. ANDERER S
    New Cardiovascular Risk Calculator Could Reduce Blood Pressure Medication Prescribing.
    JAMA. 2024 Aug 16. doi: 10.1001/jama.2024.15514.
    PubMed    
    
    
    
88. CURFMAN G
    Chelation Therapy Following Myocardial Infarction.
    JAMA. 2024 Aug 14. doi: 10.1001/jama.2024.13549.
    PubMed    
    
    
    
89. LAMAS GA, Anstrom KJ, Navas-Acien A, Boineau R, et al
    Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial.
    JAMA. 2024 Aug 14:e2411463. doi: 10.1001/jama.2024.11463.
    PubMed     Abstract available
    
    
    July 2024
90. KHAN SS, Lloyd-Jones DM
    Statins for Primary Prevention of Cardiovascular Disease-With PREVENT, What's a Clinician to Do?
    JAMA. 2024 Jul 29. doi: 10.1001/jama.2024.13887.
    PubMed    
    
    
    
91. GRANT JK, Ndumele CE, Martin SS
    The Evolving Landscape of Cardiovascular Risk Assessment.
    JAMA. 2024 Jul 29. doi: 10.1001/jama.2024.13247.
    PubMed    
    
    
    
92. DIAO JA, Shi I, Murthy VL, Buckley TA, et al
    Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations.
    JAMA. 2024 Jul 29:e2412537. doi: 10.1001/jama.2024.12537.
    PubMed     Abstract available
    
    
    
93. GERMAN CA, Davis AM, Polonsky TS
    Management of Patients With Chronic Coronary Disease.
    JAMA. 2024 Jul 24. doi: 10.1001/jama.2024.9813.
    PubMed    
    
    
    
94. YEH RW, Kirtane AJ
    Coronary In-Stent Restenosis Treated With Paclitaxel-Coated Balloon vs Uncoated Balloon-Reply.
    JAMA. 2024;332:169-170.
    PubMed    
    
    
    
95. KRATKA A, Redberg RF
    Coronary In-Stent Restenosis Treated With Paclitaxel-Coated Balloon vs Uncoated Balloon.
    JAMA. 2024;332:169.
    PubMed    
    
    
    
96. NICHOLLS SJ, Lam CSP, Nelson AJ
    Cardiovascular Clinical Trials in the Asia-Pacific Region.
    JAMA. 2024 Jul 1. doi: 10.1001/jama.2024.6313.
    PubMed    
    
    
    June 2024
97. ANDERER S
    New Research Could Help Explain Anger's Link to Heart Attacks and Strokes.
    JAMA. 2024;331:2065-2066.
    PubMed    
    
    
    
98. LARKIN H
    New Cardiovascular Disease Risk Calculator Could Eliminate the Need for Statins for Millions.
    JAMA. 2024 Jun 21. doi: 10.1001/jama.2024.8590.
    PubMed    
    
    
    May 2024
99. HARRIS E
    beta-Blockers After Heart Attacks Might Not Lower Deaths for Some.
    JAMA. 2024;331:1698.
    PubMed    
    
    
    
100. NEUMANN JT, Twerenbold R, Weimann J, Ballantyne CM, et al
     Prognostic Value of Cardiovascular Biomarkers in the Population.
     JAMA. 2024 May 13:e245596. doi: 10.1001/jama.2024.5596.
     PubMed     Abstract available
     
     
     
101. GAZIANO TA, Gaziano JM
     Can Cardiovascular Risk Assessment Be Improved in the 21st Century?
     JAMA. 2024 May 13. doi: 10.1001/jama.2024.7644.
     PubMed    
     
     
     
102. SELVARAJ S, Claggett B, Shah SH, Mentz RJ, et al
     Cardiovascular Burden of the V142I Transthyretin Variant.
     JAMA. 2024 May 12:e244467. doi: 10.1001/jama.2024.4467.
     PubMed     Abstract available
     
     
     
103. AGGARWAL R, Ostrominski JW, Vaduganathan M
     Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020.
     JAMA. 2024 May 8:e246892. doi: 10.1001/jama.2024.6892.
     PubMed    
     
     
     April 2024
104. MCCARTHY CP, Wasfy JH, Januzzi JL Jr
     Is Myocardial Infarction Overdiagnosed?
     JAMA. 2024 Apr 24. doi: 10.1001/jama.2024.5235.
     PubMed    
     
     
     
105. HARRIS E
     Study Examines Intermittent Fasting and Cardiovascular Mortality.
     JAMA. 2024 Apr 12. doi: 10.1001/jama.2024.5158.
     PubMed    
     
     
     
106. WU F, Jacobs DR Jr, Daniels SR, Kahonen M, et al
     Non-High-Density Lipoprotein Cholesterol Levels From Childhood to Adulthood and Cardiovascular Disease Events.
     JAMA. 2024 Apr 12. doi: 10.1001/jama.2024.4819.
     PubMed     Abstract available
     
     
     March 2024
107. HARRIS E
     Plastic in Arteries Tied With Higher Risk of Cardiovascular Problems.
     JAMA. 2024 Mar 29. doi: 10.1001/jama.2024.3707.
     PubMed    
     
     
     
108. YEH RW, Shlofmitz R, Moses J, Bachinsky W, et al
     Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial.
     JAMA. 2024;331:1015-1024.
     PubMed     Abstract available
     
     
     
109. KUNDU A, Moliterno DJ
     Drug-Coated Balloons for In-Stent Restenosis-Finally Leaving Nothing Behind for US Patients.
     JAMA. 2024;331:1011-1012.
     PubMed    
     
     
     
110. HARRIS E
     Meta-Analysis: Cardiovascular Risks Rose After Stopping Aspirin.
     JAMA. 2024 Mar 22. doi: 10.1001/jama.2024.2091.
     PubMed    
     
     
     
111. XU J
     Sintilimab and Cardiovascular Toxicity-Reply.
     JAMA. 2024 Mar 21. doi: 10.1001/jama.2024.0676.
     PubMed    
     
     
     
112. PENG L, Yang D, Weng C
     Sintilimab and Cardiovascular Toxicity.
     JAMA. 2024 Mar 21. doi: 10.1001/jama.2024.0673.
     PubMed    
     
     
     
113. CHEN G, Shang M, Yang Y
     Traditional Chinese Medicine Compound and Clinical Outcomes in Acute Myocardial Infarction-Reply.
     JAMA. 2024 Mar 20. doi: 10.1001/jama.2024.0617.
     PubMed    
     
     
     
114. ZAKIEV V, Gvozdeva A, Skotnikov A
     Traditional Chinese Medicine Compound and Clinical Outcomes in Acute Myocardial Infarction.
     JAMA. 2024 Mar 20. doi: 10.1001/jama.2024.0620.
     PubMed    
     
     
     
115. ASHAM H, Entezari-Maleki T
     Traditional Chinese Medicine Compound and Clinical Outcomes in Acute Myocardial Infarction.
     JAMA. 2024 Mar 20. doi: 10.1001/jama.2024.0623.
     PubMed    
     
     
     
116. HARRIS E
     Blood Test Predicted Risk of Future Heart Attacks.
     JAMA. 2024;331:908.
     PubMed    
     
     
     
117. ANDERER S
     Cannabis Use Linked to Elevated Myocardial Infarction and Stroke Risk.
     JAMA. 2024 Mar 15. doi: 10.1001/jama.2024.2075.
     PubMed    
     
     
     
118. KO D, Pascual-Leone A, Shah SJ
     Use of Lecanemab for Patients With Cardiovascular Disease: The Challenge of Uncertainty.
     JAMA. 2024 Mar 15. doi: 10.1001/jama.2024.2991.
     PubMed    
     
     
     
119. HARRIS E
     High Niacin Levels May Raise Cardiovascular Disease Risk.
     JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1566.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum